ARCHIVES

Cephalon To Plead Guilty, Pay $425M For Off-Label Marketing.

This article is from The Cancer Letter archive.

Vol. 34 No. 36 | October 3, 2008

Download PDF Visit The Full Archive

Related Articles

Upton Prefers Keeping Bioassay Program In NCI

May 12, 1978

NCI Plans $175 Million In Program Cuts To Cover Deficit, Fund New Initiatives

November 17, 2006

FDA to Move Away From Central Radiology To Investigator Review In PFS Endpoint Trials

July 27, 2012

Senate Confirms FDA Commissioner Von Eschenbach.

December 8, 2006

NCI’s Weinstein Said He Never Pressured Researcher

November 3, 1995

Cell Genesys Begins Phase II Trial Of Gvax Vaccine For Pancreatic Cancer.

November 30, 2001